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Noon
1116-1 Preconditioning of the Diabetic Myocardium With Acute 
Metformin Treatment
Aman K. Kakkar, James J. Greer, William H. Bestermann, David J. Lefer, Louisiana State 
University Health Sciences Center, Shreveport, LA
Metformin is a widely used drug for the treatment of type 2 diabetes mellitus. Metformin
activates AMP-activated protein kinase and suppresses lipogenic transcription factors
such as sterol regulatory element binding protein-1 (SREBP-1). We investigated the
effects of acute metformin treatment on the severity of acute myocardial infarction in both
nondiabetic and diabetic mice.
Mice were subjected to left anterior descending coronary artery occlusion (MI) for 30
min. followed by 24 hr. of reperfusion (R). Myocardial area-at-risk (AAR) was determined
with in vivo Evans Blue dye injection and myocardial infarct size (INF) was measured
using TTC staining. db/db diabetic mice and nondiabetic mice (10 weeks of age) were
injected (i.p.) with metformin (0.25 mg/Kg) 18 hours before the onset of MI.
Serum glucose levels were 94±6 mg/dL in nondiabetic mice and 323±16 mg/dL in db/db
diabetic mice (p<0.01 between groups). Metformin treatment did not alter serum glucose
levels at the time of MI. Data for myocardial infarct size in nondiabetic mice are shown in
Figure 1. Acute treatment with metformin significantly (p<0.001) reduced INF/AAR in
nondiabetic mice. Data for myocardial infarct size in db/db diabetic mice treated with met-
formin are shown in Figure 2. Metformin therapy also significantly (p<0.05) attenuated
the extent of myocardial infarction in the db/db diabetic mouse heart.
We conclude that acute metformin treatment protects against myocardial infarction in
both nondiabetic and diabetic mice. 
Noon
1116-2 Delivery of Human Myoblasts Transduced With a Novel 
Bicistronic Vector Carrying Human Vascular Endothelial 
Growth Factor 165 and Angiopoietin-I Forms Mature 
Blood Vessel in the Heart
Lei Ye, Husnain Kh Haider, Ruowen Ge, Peter K. Law, Terrance Chua, Salim Aziz, 
Eugene KW Sim, National University of Singapore, Singapore, Singapore, National 
University Medical Institute, Singapore, Singapore
Backgrounds
We hypothesized that synergy between VEGF165 and angiopoietin-1 (Ang-1) by using a
novel bicistronic vector encoding for two growth factors may lead to better prognosis
when delivered using human myoblasts.
Methods
Human myoblasts carrying lac-z reporter gene were transduced with adenovirus carrying
bicistronic vector encoding for human VEGF165 and Ang-1. The transduced myoblasts
were functionally assessed by immunostaining and RT-PCR. Myocardial infarction model
was created in 17 female swines by coronary artery ligation and grouped as DMEM
injected (group-1 n= 6), myoblast transplanted (group-2 n= 5), and myoblast carrying
bicistronic vector (group-3 n=6). Three weeks later, 5 ml basal DMEM with 3x108 cells or
without cells was injected intramyocardially in and around the infarct and immunosup-
pressed for six weeks using 5mg /kg cyclosporine. The animal was euthanized and the
heart was explanted at 6-12 weeks post cell transplantation and processed for histologi-
cal studies.
Results
High transduction efficiency of myoblasts (>98%) was achieved by multiple transduction
procedure. Myobalsts efficiently secreted VEGF165 and Ang-1 simultaneously as
revealed by dual fluorescent immunostaining and RT-PCR. Extensive survival of the lac-z
positive myoblasts was observed in and around the infarct. Average vascular density at
low power field (x100) by double immunofluorescence staining for vWFactor-VIII and
smooth muscle actin in group-3 (25.07±3.54; 23.71±3.15) was significantly higher than
group-1 (16.0±2.56 p<0.01; 7.87±1.46 p<0.01), group-2 (16.22±3.15 p<0.01; 11.89±3.06
p<0.01) respectively at 6 weeks post treatment. The mature blood vessels count in
group-3 was the highest (94.6%). Regional blood flow (ml/min/g) at 6 weeks improved in
group-3 (3.00± 0.37) significantly as compared to group-1 (1.22± 0.45 p<0.01) and
group-2 (1.12± 0.14 p<0.01). The Ejection fraction in bicistronic group-3 was 43.0
±10.4% which was significantly higher than the control group-1 (34.67±15.37, p<0.05).
Conclusion
Multiple growth factor gene delivery using myoblast as a carrier leads to angiomyogene-
sis with higher percentage of mature blood vessel formation.
Noon
1116-3 Regulation of Intercellular Adhesion Molecule-1 
Transcription in Ischemic-Reperfused Myocardium 
Through STAT3 Activation
Xiao Ping Yang, Anthony DiPaula, Jr., Lewis C. Becker, Johns Hopkins University School 
of Medicine, Baltimore, MD
Intercellular adhesion molecule-1 (ICAM-1) is rapidly upregulated on endothelial cells
(ECs) during ischemia-reperfusion (I-R) and mediates tissue leukocyte accumulation and
subsequent cell injury. Different from other adhesion molecules, the ICAM-1 proximal
promoter contains a STAT1/STAT3 motif (GAS sequence). Because this motif flanks an
SP1 binding site which is very close to the TATA box, it may be important for regulation of
ICAM-1 transcription. To study the role of STAT after myocardial I-R, open chest anesthe-
tized rats underwent anterior descending coronary artery occlusion for 35 min and reper-
fusion (R) for 0, 15, 30, 60, 120, or 240 min. Myocardial samples were rapidly frozen and
analyzed for STAT activation (gel shift and immunoprecipitation), ICAM-1 mRNA level
(real-time R-T PCR) and tissue cytokines (multiplexed sandwich ELISA). STAT was acti-
vated by 15 min R and peaked at 60 min R. Gel supershift assay identified the activated
STAT isoform as STAT3 without STAT1. ICAM-1 mRNA level increased rapidly at 30 min
R, and remained increased through 120 min R. Coimmunoprecipitation of nuclear extract
indicated that STAT3 was bound to SP1, suggesting possible transcriptional cooperativity.
Cytokine assay showed an increase in myocardial IL-6 during I-R. To determine whether
activated STAT3 could regulate ICAM-1 transcription in ECs, cultured human cardiac
microvascular endothelial cells were exposed to IL-6, 40 ng/ml. Phosphorylated STAT3
was identified by immunoprecipitation within 15 min, and ICAM-1 mRNA increased
shortly afterwards at 30 min after IL-6 exposure. Transfection of a GAS decoy oligonucle-
otide to inhibit STAT3 partially blocked IL6-induced ICAM-1 mRNA expression. The
results indicate that STAT3 is activated very quickly in the myocardium following I-R,
interacts with SP1 in the nucleus, and is responsible for rapid upregulation of ICAM-1
transcription.
Noon
1116-4 Consequences of Hemodynamic Instability After 
Carotid Artery Stenting
Alex Abou-Chebl, Rishi Gupta, Christopher T. Bajzer, H. Christian Schumacher, Jay S. 
Yadav, The Cleveland Clinic Foundation, Cleveland, OH
Purpose: To determine if hemodynamic instability (HI) during extracranial carotid artery
stenting (CAS) increases the risk of adverse events.
Background: CAS has been utilized in patients considered at high risk for carotid endar-
terectomy (CEA). HI is a known side effect of carotid sinus stimulation induced by CEA
and CAS. Recent literature suggests that the presence of HI may increase the risk of
adverse cardiovascular events following CEA, however the frequency and consequences
of HI have not been systematically evaluated in a large population of patients undergoing
CAS.
Methods: Patients with HI were identified from the carotid stent registry maintained at
The Cleveland Clinic Foundation. This is a prospectively collected database of all
patients undergoing extracranial CAS for atherosclerotic lesions between 1999-2002. In
addition, the medical records of all CAS patients were retrospectively reviewed to identify
patients with peri-procedural HI who may have been missed by the database. HI was
defined as symptomatic or asymptomatic hypotension (systolic blood pressure < 90) or
braycardia (heart rate < 60). The use of vasopressors or atropine and all peri-procedural
adverse events were study endpoints.
Results: A total of 404 consecutive patients with a mean age of 70.5 ± 9.8 yrs were stud-
ied. Sixty four percent were men. The mean stenosis severity was 85.6 ± 10.1%. Peri-
procedural hypotension occurred in 113 (28%) patients and required vasopressors in 85
% WOMEN IN POSTGRADUATE TRAINING (1992-2001) (rate of change)
Field Minimum % 
women
Maximum % 
women
r (linear 
regression)
Slope P value Cardiol vs 
others (P<0.05=sig)
Cardiol 9.76 15.50 0.94 0.608
 ----
Ob-Gyn
48.10
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0.99 2.36
<0.001
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25.60 38.20 0.97 1.34 <0.001
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(21%) patients. Peri-procedural bradycardia occurred in 99 (24.5%) patients but only 61
(15%) required atropine. Patients with HI had a significantly increased risk of stroke
(OR=2.6, 95% CI 1.2-5.9), myocardial infarction (MI) (OR=4.5, 95% CI 1.2-16.9) or death
(OR=2.7, 95% CI 1.0-7.6) in the peri-operative period. The odds ratio for the combined
endpoint of stroke, MI or death was 3.6 (95% CI 1.8-6.9) in patients with HI.
Conclusions: HI is common after CAS and often requires pharmacological intervention.
Patients with HI are at an increased risk for stroke, MI or death and require close monitor-
ing.
Noon
1116-5 Elevated Preprocedural C-Reactive Protein Levels 
Predict Death and Stroke in Patients After Carotid 
Artery Stenting
David S. Lee, Michael H. Yen, Anjli Maroo, Ravish Sachar, Jakob Schneider, Mary Ellen 
Satava, Samir R. Kapadia, Deepak L. Bhatt, Christopher T. Bajzer, Jay S. Yadav, 
Cleveland Clinic Foundation, Cleveland, OH
Background: Elevated pre-procedural C-reactive protein (CRP) levels are associated
with the composite endpoint of death or myocardial infarction in patients undergoing per-
cutaneous coronary intervention.We sought to determine whether elevated pre-proce-
dural CRP levels predict the composite endpoint of death or stroke in patients who
undergo carotid artery stenting.
Methods: Between December 1999 and August 2002, we examined 133 patients with
pre-procedural CRP levels who underwent carotid artery intervention from a carotid inter-
ventional registry. Using a CRP level of 3.0 mg/L as the cutoff, patients were sub-divided
into high CRP (n=67) and low CRP (n=66) groups. The 30 day and 12 month composite
endpoint of death or stroke were compared between the groups.
Results: No significant differences in baseline demographics were found between the
two groups (including age, gender, coronary artery disease, or prior stroke or transient
ischemic attack), except for hyperlipidemia which was significantly higher in the low CRP
group. For the entire cohort, the death/stroke rates at 30 days and 12 months were 5% (7
events) and 12% (16 events) respectively. The 30 day death/stroke rate was significantly
higher in the high CRP group vs. the low CRP group (10% vs. 0%, p<0.01). This
increased event rate was sustained at one year (19% vs. 5%, p<0.01).
Conclusion: In patients who undergo carotid artery stenting, pre-procedural CRP levels
predict the composite endpoint of death or stroke at 30 days and 12 months.
Noon
1116-6 Long-Term Clopidogrel Therapy Following 
Percutaneous Coronary Intervention Improves Clinical 
Outcome but Is Not Associated With Increased 
Bleeding: New Insights From the CREDO Trial
Herbert D. Aronow, Steven R. Steinhubl, Danielle M. Brennan, Eric J. Topol, Cleveland 
Clinic Foundation, Cleveland, OH, University of Pennsylvania, Philadelphia, PA
Background: In the CREDO trial, the 1-year incidence of major adverse clinical events
(MACE) among patients undergoing or likely to undergo coronary stenting was signifi-
cantly reduced by a pre-procedure clopidogrel loading dose plus 1 year of clopidogrel
compared with no loading dose and 28 days of clopidogrel. Because most patients
undergoing coronary stenting receive 4 weeks of dual antiplatelet therapy with aspirin
and clopidogrel, we sought to determine predictors of bleeding and occurrence of major
events between day 29 and 1 year among patients enrolled in the CREDO trial.
Methods: Patients who survived to day 29 were included (n=2068) in this intent-to-treat
analysis. Minor and major bleeding events (TIMI criteria) were pooled into a composite of
any bleeding. MACE was a composite of death, non-fatal myocardial infarction (MI) and
stroke.
Results: From day 29 through 1 year there were 138 bleeding events, 68 in the clopi-
dogrel and 70 in the placebo arm (p=0.84). Of these, 112 (81%) were procedure-related,
and most (82, 59%) occurred in the setting of coronary artery bypass graft surgery
(CABG). In a multivariable model including demographics, comorbidities and concomi-
tant medical therapies, the only significant independent predictors of bleeding were
increasing age, diabetes (DM), and CABG (model chi square 398, p < 0.001, c statistic
0.85); clopidogrel therapy beyond 28 days was not a significant predictor of major or
minor bleeding. During that same interval, 80 MACE occurred. First MACE was signifi-
cantly less frequent among those randomized to clopidogrel than placebo (3.0 vs. 4.7%,
p=0.043).
Conclusions: With the sustained use of dual antiplatelet therapy from 1 month to one
year after percutaneous coronary intervention, there is a significant 36% reduction of
death, MI, and stroke without any increase in bleeding events.
Noon
1116-7 Similar Outcomes Between Patients With Native 
Coronary and Bypass Graft Disease Treated With 
Sirolimus-Eluting Stents in the SECURE Trial
Costa Marco, Teirstein Paul, MB Leon, Theodore Bass, Tim Fischell, Andrew Carter, 
Yakubov Steven, University of Florida Jacksonville, Jacksonville, FL, FL
Background: Bare metal stenting or CABG has provided limited success for the treatment
of bypass graft disease. The efficacy of Sirolimus-eluting Bx Velocity stents (SES) in
native coronary arteries is proven, however its application in bypass grafts remains
unknown. We compared the long-term results between patients with native coronary dis-
ease versus those with graft disease treated with sirolimus-eluting stents as part of
SECURE trial.
Methods and Results: Patients (n=252) with a serious disease or condition for which
there was no acceptable alternative treatment available were enrolled. Out of 202
patients with complete 6-month follow-up, 58 patients had 75 graft lesions (GI) and 144
patients had 286 lesions in native vessels (GII). There were more males in GI(83%) ver-
sus GII (67%). Other baseline characteristics were similar, with 39% diabetics in each
group. 71% of lesions in GI and 58% of lesion in GII were treated with previous brachy-
therapy. All patients received aspirin and clopidogrel for at least 6 months. Angiographic
vessel diameter, determined by the core lab, was larger in GI (2.26mm) versus GII
(1.92mm). Likewise, in-stent MLD post procedure was 2.52mm (GI) and 2.18mm (GII).
Mean total stent length was 23.3mm in both groups. There was no in-hospital adverse
event in GI and 1 death (0.7%) in GII. After 6 months, 13.8% of patients in GI versus
10.4% of patients in GII had at least one major adverse event (death, myocardial infarc-
tion, target lesion revascularization or emergent CABG). TVR rate was 12.1% in GI and
9% in GII. Updated data with angiographic follow-up will be available for presentation.
Conclusion: In the SECURE trial, which enrolled a very high risk group of patients, the
use of sirolimus-eluting stent to treat bypass graft disease was feasible, safe and pro-
vided acceptable long-term results compared to the outcomes of patients with native cor-
onary disease.
Noon
1116-8 Early and Mid-Term Results of Cypher Stents in 
Unprotected Left Main
Alaide Chieffo, Dejan Orlic, Flavio Airoldi, Iassen Michev, Matteo Montorfano, Nicola 
Corvaja, Ghada W Mikhail, Davide Maccagni, Antonio Colombo, San Raffaele Hospital, 
Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
The safety and efficacy of percutaneous coronary intervention in unprotected left main
(ULM) coronary arteries confronts with the problems associated with restenosis.
Methods From April 2002 32 consecutive patients were electively treated in our instution
with the implantation of Cypher (Cordis, Johnson and Johnson Company, Warren,
NJ)Sirolimus-eluting stent (SES) in unprotected left main.
Results 4 patients (12.5%) were diabetics, 7 (22%) had unstable angina, mean age was
58±13 years, and EF was 51± 6.6 %. The site of the lesion in LM was ostial in 3 (9.3%)
patient, mid-portion of the artery in 3 patients (9.3%) and distal in 27 ( 84.3%) patients
(bifurcation in 21pts and trifurcation in 6). In 19 (70%) patients with distal LM disease
both branches were stented with SES, kissing balloon inflation was performed in 15
(55.5%). Only POBA in side branch was performed in 3 patients (11%), 5 pts had no
treatment in the side branch. The largest nominal diameter of SES available was 3.0 mm
(6 cells). Angiographic as well as procedural success was achieved in all patients. Elec-
tive intra-aortic balloon pump was used in 4 patients and GP IIb/IIIa antagonists were
used in 16 (50 %) patients. During hospitalization, no patient died, nor had myocardial
infarction (MI) or CABG , one patient had repeated PTCA due to residual dissection distal
to the Cypher stent. At 6 month clinical follow-up 1 patient died after discontinuing antiag-
gregant theraphy because of acute pancreatisis, 6 (18.7%) patients had TLR (4 re-PCI
and 2 CABG) and 1 had MI. Angiographic follow-up was achieved in 23 pts (74%). Rest-
enosis occurred in 6 patients; all restenostic lesions were located in the distal LM.
Conclusions In this early experience with Cypher stents in ULM we can state that the
problem of in-stent restenosis is still present mainly at the level of the bifurcation. We can
speculate that the usage of 3 mm stents (6 cells) in vessels usually larger than 3.5mm
could have contributed to inhomogeneous drug delivery to the vessel wall.
Noon
1116-9 Trends in Fibrinolytic Therapy and Intra-Aortic Balloon 
Pump Counterpulsation Utilization in Patients With 
Cardiogenic Shock Complicating Acute Myocardial 
Infarction in Hospitals Without Percutaneous 
Transluminal Coronary Angioplasty/Coronary Artery 
Bypass Graft Capability: Observations From the 
National Registry of Myocardial Infarction
Anvar A. Babaev, Paul D. Frederick, Delia Cotiga, Judith S. Hochman, NYU Medical 
Center, New York, NY, Ovation Research Group, Seattle, WA
Background: Treatment of patients (pts) in cardiogenic shock (CS) complicating acute
myocardial infarction (AMI) with fibrinolytic therapy (FT) and intra-aortic balloon pump
counterpulsation (IABP) in hospitals without PTCA/CABG capability is associated with
mortality reduction.
Objectives: We determined trends in utilization of FT, IABP, and mortality rates for
patients in CS complicating AMI in the National Registry of Myocardial Infarction (NRMI)
population for hospitals without PTCA/CABG capability.
